Overview

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153

Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
RV6153 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The main purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of RV6153
Phase:
Phase 1
Details
Lead Sponsor:
Respivert Ltd